Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $13.60.

Several equities analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Orchestra BioMed in a research note on Thursday, May 14th. Chardan Capital reissued a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Thursday, March 12th. B. Riley Financial cut their target price on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Barclays raised their target price on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen downgraded shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th.

Orchestra BioMed Trading Down 0.5%

Shares of OBIO opened at $4.30 on Friday. The stock’s 50-day moving average price is $4.03 and its 200 day moving average price is $4.19. The company has a quick ratio of 7.01, a current ratio of 7.03 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $257.48 million, a price-to-earnings ratio of -4.43 and a beta of 0.49. Orchestra BioMed has a 12-month low of $2.20 and a 12-month high of $5.42.

Orchestra BioMed (NASDAQ:OBIO) last issued its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%.The business had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.92 million. As a group, research analysts predict that Orchestra BioMed will post -1.47 earnings per share for the current year.

Insider Activity

In other news, insider Darren Sherman sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $3.87, for a total value of $58,050.00. Following the completion of the transaction, the insider owned 1,184,327 shares in the company, valued at $4,583,345.49. This trade represents a 1.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Eric S. Fain purchased 20,000 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was bought at an average price of $4.13 per share, with a total value of $82,600.00. Following the completion of the purchase, the director owned 91,709 shares of the company’s stock, valued at approximately $378,758.17. This represents a 27.89% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 39,636 shares of company stock valued at $158,081 in the last quarter. Company insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Orchestra BioMed

Large investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. bought a new position in shares of Orchestra BioMed during the third quarter worth approximately $3,386,000. Pathstone Holdings LLC acquired a new position in Orchestra BioMed in the 3rd quarter valued at $2,495,000. Vanguard Group Inc. grew its holdings in Orchestra BioMed by 28.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock valued at $3,675,000 after buying an additional 324,558 shares in the last quarter. Simplify Asset Management Inc. bought a new position in Orchestra BioMed during the 1st quarter worth $932,000. Finally, 683 Capital Management LLC acquired a new stake in shares of Orchestra BioMed during the fourth quarter worth $847,000. Institutional investors own 53.20% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.